15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for DRMA yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $1.59 current
Highest Target—
Average Target—
Lowest Target—
DRMA analyst recommendation trends
86420
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Strong BuyBuyHoldSellStrong Sell
RATING
FEB
MAR
APR
MAY
JUN
JUL
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Hold
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Jul, 1 of 1 firms rate DRMA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DRMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.46 – $-0.46 · 1 analysts · -70% YoY
Next period, 1 analysts expect Dermata Therapeutics Inc to earn $-0.46 a share (range $-0.46 – $-0.46), versus $-1.52 a year earlier. Full-year consensus is $-2.17, growing to $-1.43 the year after.
REVENUE · NEXT QUARTER
$75.0K
Range $75.0K – $75.0K · 1 analysts
Revenue is expected to reach $75.0K (range $75.0K – $75.0K). Full-year consensus is $100.0K, rising to $750.0K next year.
Top analysts covering Dermata Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DRMA.
#1
Anthony Vendetti
Maxim Group · Rank #350
Buy
$10.00+528.9% to target
Overall win rate
29%
+ Follow
DRMA stock forecast FAQ
Who is the most accurate analyst covering DRMA?+
Among analysts who currently cover DRMA, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $10.00 target.
What is Dermata Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.46 – $-0.46) across 1 analysts. Full-year EPS is projected at $-2.17, rising to $-1.43 the following year.
How much revenue is Dermata Therapeutics Inc expected to report next quarter?+
Consensus revenue is $75.0K (range $75.0K – $75.0K). Full-year revenue is projected at $100.0K, growing to $750.0K next year.
Have analysts been upgrading or downgrading DRMA lately?+
As of Jul, 1 of 1 firms rate DRMA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DRMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
